Share on StockTwits

Shares of Smith & Nephew plc (NYSE:SNN) have been given a consensus recommendation of “Hold” by the sixteen brokerages that are presently covering the company, ARN reports. Nine analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $97.00.

Smith & Nephew plc (NYSE:SNN) opened at 88.33 on Friday. Smith & Nephew plc has a 1-year low of $57.99 and a 1-year high of $100.90. The stock’s 50-day moving average is $87.6 and its 200-day moving average is $82.46. The company has a market cap of $15.793 billion and a P/E ratio of 30.02.

Smith & Nephew plc (NYSE:SNN) last posted its quarterly earnings results on Friday, August 1st. The company reported $1.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.08. On average, analysts predict that Smith & Nephew plc will post $4.21 earnings per share for the current fiscal year.

A number of research firms have recently commented on SNN. Analysts at Morgan Stanley downgraded shares of Smith & Nephew plc from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 15th. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Receive News & Ratings for Smith & Nephew plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.